Isoniazid Alliance Pharmaceuticals (Isoniazid)

Isoniazid inhibits the bacterial enzyme InhA, blocking the synthesis of mycolic acids that are vital for the mycobacterial cell wall. This interference weakens the cell wall, leading to bacterial death, especially in actively replicating Mycobacterium tuberculosis organisms.

The specific dose of isoniazid is determined by the prescribing clinician based on the patient’s age, weight, disease status, and renal or hepatic function. Dosing regimens are individualized and should follow local treatment guidelines and the prescriber’s judgment.

Safety data for isoniazid during pregnancy and lactation are limited. The drug is classified as a potential risk, and its use should be considered only when the benefits to the mother outweigh any possible risks to the fetus or infant. Consultation with a healthcare professional is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

Isoniazid is a first‑line agent with potent activity against replicating Mycobacterium tuberculosis, often used in combination with rifampicin, pyrazinamide and ethambutol. Compared with newer agents, it is inexpensive and well‑studied, but it carries a higher risk of hepatotoxicity and peripheral neuropathy, necessitating monitoring and pyridoxine supplementation.

Isoniazid injectable should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and avoid freezing. Follow any additional handling instructions provided on the label.

Isoniazid Alliance Pharmaceuticals is supplied as a sterile injectable solution for intramuscular, intrapleural or intrathecal administration. The route and frequency are determined by the treating physician, who will select the appropriate injection site and dosing schedule based on clinical guidelines.

The most serious adverse events include severe hepatitis, which may present with jaundice, fatigue or abdominal pain, and rare hypersensitivity reactions such as Stevens‑Johnson syndrome or anaphylaxis. Neurological complications like peripheral neuropathy can also be significant if pyridoxine is not co‑administered.

Isoniazid is contraindicated in individuals with a known hypersensitivity to the drug or any of its components. Patients with severe hepatic impairment, active liver disease, or pre‑existing peripheral neuropathy without pyridoxine supplementation should avoid its use unless closely monitored.